Myeloid Therapeutics Appoints Leading Immunologist, Cell & Gene Therapy Expert Bruce McCreedy, Ph.D.
Dr. McCreedy brings decades of executive-level biopharmaceutical experience to advance research and development of novel myeloid-targeting therapies. CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ — Myeloid Therapeutics, Inc., a clinical-stage immunology company that is combining RNA insights with new technology to develop powerful cancer therapies, today announced that industry veteran Bruce McCreedy, Ph.D., has joined the […]
Industry veteran will draw on unique mix of scientific and business acumen to support Company’s efforts to combat cancer with growing portfolio of novel myeloid-targeting therapies CAMBRIDGE, Mass., March. 31, 2021 /PRNewswire/ — Myeloid Therapeutics, Inc., a clinical-stage immunology company focused on combining RNA insights with cutting edge technologies for new cancer therapies, today announced […]
Myeloid’s cell therapy harnesses the innate capabilities of myeloid lineage cells to fight cancer. Scientific founders include world-renowned cell therapy & cancer experts Ronald Vale, Ph.D. and Siddhartha Mukherjee, M.D., D.Phil. Co-Founded by Thomas Cahill, M.D., Ph.D., with financing led by Newpath Partners and participation from leading biotech investors CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ […]
CAMBRIDGE, Mass., June 2, 2020 – Myeloid Therapeutics, a biotech company harnessing the innate immune system to eradicate cancer and other diseases, today announced a presentation at the Jefferies 2020 Virtual Healthcare Conference. Chief Scientific Officer Daniel Getts, Ph.D., will give a company overview and provide an update on its lead oncology and COVID-19 programs […]